All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Gedatolisib, Fulvestrant, and Palbociclib Triplet Under Investigation in HR+/HER2– Breast Cancer

May 4th 2023

The combination of gedatolisib and fulvestrant with or without palbociclib is under evaluation in the phase 3 VIKTORIA-1 trial for the treatment of patients with PIK3CA-mutated or wild-type hormone receptor–positive/HER2-negative breast cancer who have previously progressed on first-line therapy.

Early ctDNA Testing Provides Another Tool for Predicting Survival Outcomes With Tebentafusp in Metastatic Uveal Melanoma

May 4th 2023

Ryan J. Sullivan, MD, discusses previous research on tebentafusp in uveal melanoma that led to the inception of the IMCgp100-202 trial and clinical implications for data confirming the predictive value of circulating tumor DNA levels.

Individual Patient Factors Drive Treatment Decisions in MPNs

May 4th 2023

Onco-nursing experts highlight the best practices and latest treatment regimens for patients presenting with the 3 most common myeloproliferative neoplasms: myelofibrosis, polycythemia vera, and essential thrombocythemia.

Temple Health Launches New Fox Chase-Temple Urologic Institute

May 4th 2023

Fox Chase Cancer Center and Temple Health are pleased to announce the new Fox Chase-Temple Urologic Institute, a groundbreaking initiative that will concentrate on both benign and oncologic urology.

FDA Approves Companion Diagnostic for Mobocertinib in Advanced NSCLC With EGFR Exon 20 Insertion Mutations

May 4th 2023

The FDA has approved FoundationOne® Liquid CDx as a companion diagnostic for mobocertinib in patients with locally advanced or metastatic non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

Giants of Cancer Care® Announces the 11th Annual Class of Inductees

May 4th 2023

OncLive®, the nation’s leading multimedia resource for oncology professionals and Pfizer (platinum sponsor) and Exelixis and Stemline (gold sponsors), are pleased to announce the inductees of the 11th Annual Giants of Cancer Care recognition program.

Breadth of Biomarker Testing Continues to Inform and Guide Targeted Approaches in Lung Cancer

May 4th 2023

Balazs Halmos, MD, discusses factors to consider when selecting a biomarker assay for patients with non–small cell lung cancer, emphasizes the importance of secondary testing, provides recommendations for the treatment of patients with co-mutations, and highlights ongoing or future areas of interest for research within lung cancer.

IMX-110 Plus Tislelizumab Shows Early Activity in Advanced Metastatic Colorectal Cancer

May 3rd 2023

Treatment with the combination of IMX-110 and tislelizumab resulted in 100% tumor shrinkage at 2 months in 2 of 2 evaluable patients with advanced metastatic colorectal cancer who received the regimen at the lowest dose level examined in the dose-escalation portion of the ongoing phase 1b/2a IMMINENT-01 trial

Adagrasib Demonstrates Promising Activity in KRAS G12C–Mutated Solid Tumors

May 3rd 2023

Treatment with adagrasib monotherapy led to clinically meaningful activity and a manageable safety profile in patients with KRAS G12C–mutated solid tumors.

Richard McDonough, MD Honored for Patient Advocacy Efforts, Receives Dorothy Green Phillips Legacy Award at FLASCO Annual Gala

May 3rd 2023

Florida Cancer Specialists & Research Institute, LLC medical oncologist Richard McDonough, MD, is the recipient of the Florida Society of Clinical Oncology 2023 Dorothy Green Phillips Legacy Award.

Mirvetuximab Soravtansine Improves PFS, OS in FRα+ Platinum-Resistant Ovarian Cancer

May 3rd 2023

Mirvetuximab soravtansine-gynx led to a clinically meaningful and statistically significant improvement in progression-free survival, overall survival, and objective response rate vs single-agent chemotherapy in patients with platinum-resistant ovarian cancer whose tumors express high levels of folate receptor alpha, according to topline findings from the phase 3 MIRASOL trial.

Tamibarotene/Azacitidine Combination Under Investigation in Higher-risk MDS

May 3rd 2023

Ana Alfonso Piérola, MD, PhD, discusses the rationale for targeting retinoic acid receptor alpha in patients with higher-risk myelodysplastic syndrome, the goals of the SELECT MDS-1 trial investigating tamibarotene, and where the future of research and treatment for this patient population is headed.

Liso-cel Earns European Approval for Relapsed/Refractory LBCL After 1 Prior Therapy

May 3rd 2023

The European Commission has approved lisocabtagene maraleucel for the treatment of adult patients with diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.

Neoadjuvant Atezolizumab Followed by Adjuvant Atezolizumab May Benefit Select Patients With Early-stage NSCLC

May 3rd 2023

Karen L. Reckamp, MD, MS, discusses the rationale for evaluating patients with early-stage NSCLC who received adjuvant atezolizumab as part of the LCMC3 study and explains the significance and limitations of data from a retrospective analysis.

Elacestrant and Trastuzumab Deruxtecan Approvals Prompt Sequencing Considerations in HR+ Breast Cancer

May 3rd 2023

Manali Bhave, MD, discusses the effect of emerging therapies on the treatment landscape for patients with HR-positive, HER2-negative or -low breast cancer, highlighted her stance on sequencing decisions for these patients, and expanded on the additional work being done to optimize treatment sequencing from a growing list of options.

FDA Grants Fast Track Designation to ERAS-801 in EGFR-altered Glioblastoma

May 2nd 2023

The FDA has granted a fast track designation to ERAS-801 for the treatment of adult patients with glioblastoma harboring EGFR gene alterations.

Perioperative Toripalimab/Chemotherapy Combo Improves EFS in Resectable Stage III NSCLC

May 2nd 2023

Perioperative toripalimab plus chemotherapy generated a median event-free survival benefit vs placebo plus chemotherapy in patients with resectable stage III non–small cell lung cancer.

89Zr-DFO-girentuximab May Improve Identification, Risk Stratification of Renal Tumors

May 2nd 2023

Findings from the phase 3 ZIRCON trial showed that imaging with 89Zr-DFO-girentuximab could improve the identification and risk stratification of patients with renal tumors.

Apalutamide Plus ADT Improves PSA PFS in Biochemically Relapsed Prostate Cancer

May 2nd 2023

Apalutamide plus androgen deprivation therapy with or without abiraterone acetate and prednisone improved prostate-specific antigen progression-free survival in patients with biochemically relapsed prostate cancer, according to long-term follow-up data from the phase 3 PRESTO trial.

Siteman Cancer Center Names New Deputy Director Among Other Leadership Appointments

May 2nd 2023

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis announces several leadership changes, including a new Deputy Director, Associate Directors of Translational Research and Shared Resources, and a Deputy Associate Director of Shared Resources.